Immunovant, Inc. (NASDAQ:IMVT) Expected to Earn Q2 2025 Earnings of ($0.62) Per Share

Immunovant, Inc. (NASDAQ:IMVT) – Analysts at Zacks Research lowered their Q2 2025 earnings estimates for Immunovant in a research report issued to clients and investors on Tuesday, August 27th. Zacks Research analyst E. Bagri now expects that the company will earn ($0.62) per share for the quarter, down from their previous forecast of ($0.54). The consensus estimate for Immunovant’s current full-year earnings is ($2.11) per share. Zacks Research also issued estimates for Immunovant’s Q3 2025 earnings at ($0.61) EPS, Q4 2025 earnings at ($0.63) EPS, FY2025 earnings at ($2.45) EPS, Q1 2026 earnings at ($0.63) EPS, Q2 2026 earnings at ($0.75) EPS, Q3 2026 earnings at ($0.68) EPS, FY2026 earnings at ($2.67) EPS, Q1 2027 earnings at ($0.56) EPS and FY2027 earnings at ($2.00) EPS.

IMVT has been the topic of a number of other reports. HC Wainwright reiterated a “buy” rating and issued a $51.00 price objective on shares of Immunovant in a research note on Thursday, May 30th. Cantor Fitzgerald reissued an “overweight” rating on shares of Immunovant in a research report on Wednesday, August 7th. UBS Group dropped their target price on shares of Immunovant from $42.00 to $41.00 and set a “buy” rating on the stock in a research report on Tuesday, August 13th. Oppenheimer reduced their price target on shares of Immunovant from $50.00 to $46.00 and set an “outperform” rating for the company in a report on Monday, June 3rd. Finally, JPMorgan Chase & Co. decreased their price target on shares of Immunovant from $51.00 to $46.00 and set an “overweight” rating on the stock in a research report on Thursday, August 8th. Fifteen research analysts have rated the stock with a buy rating, According to data from MarketBeat, Immunovant presently has an average rating of “Buy” and an average price target of $48.40.

Immunovant Price Performance

Immunovant stock opened at $30.90 on Friday. Immunovant has a fifty-two week low of $19.50 and a fifty-two week high of $45.58. The firm has a fifty day moving average price of $29.05 and a two-hundred day moving average price of $29.99. The firm has a market cap of $4.52 billion, a price-to-earnings ratio of -16.26 and a beta of 0.67.

Immunovant (NASDAQ:IMVT) last posted its earnings results on Tuesday, August 6th. The company reported ($0.60) earnings per share for the quarter, missing the consensus estimate of ($0.53) by ($0.07). During the same period in the previous year, the business posted ($0.57) earnings per share.

Hedge Funds Weigh In On Immunovant

A number of hedge funds and other institutional investors have recently bought and sold shares of IMVT. Point72 Asset Management L.P. bought a new stake in Immunovant in the fourth quarter valued at about $112,356,000. Octagon Capital Advisors LP boosted its stake in Immunovant by 127.3% during the 4th quarter. Octagon Capital Advisors LP now owns 273,289 shares of the company’s stock worth $11,514,000 after acquiring an additional 1,273,289 shares during the last quarter. Armistice Capital LLC boosted its stake in Immunovant by 57.0% during the 2nd quarter. Armistice Capital LLC now owns 3,396,909 shares of the company’s stock worth $89,678,000 after acquiring an additional 1,232,909 shares during the last quarter. Vanguard Group Inc. grew its holdings in Immunovant by 11.2% during the first quarter. Vanguard Group Inc. now owns 6,478,304 shares of the company’s stock valued at $209,314,000 after purchasing an additional 650,506 shares during the period. Finally, Franklin Resources Inc. bought a new stake in Immunovant in the fourth quarter valued at approximately $22,712,000. 47.08% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other news, insider Julia G. Butchko sold 1,527 shares of the business’s stock in a transaction that occurred on Tuesday, July 9th. The stock was sold at an average price of $28.06, for a total value of $42,847.62. Following the transaction, the insider now directly owns 446,853 shares of the company’s stock, valued at approximately $12,538,695.18. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, CEO Peter Salzmann sold 4,619 shares of the business’s stock in a transaction that occurred on Tuesday, July 9th. The shares were sold at an average price of $28.06, for a total value of $129,609.14. Following the completion of the transaction, the chief executive officer now owns 1,032,097 shares in the company, valued at approximately $28,960,641.82. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Julia G. Butchko sold 1,527 shares of the stock in a transaction on Tuesday, July 9th. The shares were sold at an average price of $28.06, for a total value of $42,847.62. Following the completion of the transaction, the insider now owns 446,853 shares in the company, valued at $12,538,695.18. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 31,475 shares of company stock valued at $904,638. 5.90% of the stock is currently owned by insiders.

Immunovant Company Profile

Immunovant, Inc, a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia.